KELOWNA, BC, Aug. 27, 2025 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company"), an innovator in precision-formulated oral stimulants, is pleased to announce that, further to its news release of August 19, 2025, it has closed the acquisition of the "Feed That Brain" division operated by Joseph Mimran & Associates Inc. (the "Vendor") and has completed the issuance to the Vendor of 175,000 common shares (each a "Share") at a deemed price of $1.00 per Share satisfying the first payment required pursuant to the asset purchase and sale agreement executed between the parties.
The Shares issued to the Vendor are subject to a four-month hold period in accordance with Securities Laws in Canada.
About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)
Doseology is a biotech innovation company, engineering precision-formulated oral stimulants that optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we're pioneering next-gen performance solutions designed to empower peak performance.
On behalf of the Board of Directors,
Chris Jackson
CEO
Doseology Sciences Inc.
For more information, please contact the Company at:
Email:hello@doseology.com
Website:www.doseology.com
Phone: 604.908.3095
Forward Looking Statements
This press release contains statements that constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.
No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The CSE does not accept responsibility for the adequacy or accuracy of this release.
Logo - https://mma.prnewswire.com/media/2753081/5479278/Doseology_Sciences_Inc_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/doseology-completes-acquisition-of-feed-that-brain-302539841.html
